期刊文献+

血清癌胚抗原、糖类抗原125、糖类抗原153单独及联合检测对乳腺癌的诊断价值

Diagnostic value of single and combined detection of serum carcinoembryonic antigen,carbohydrate antigen 125 and carbohydrate antigen 153 for breast cancer
下载PDF
导出
摘要 目的探讨血清癌胚抗原(CEA)、糖类抗原(CA)125、CA153单独及联合检测对乳腺癌的诊断价值。方法选取172例行乳腺癌手术的乳腺疾病患者,根据术后病理结果分为乳腺癌组(92例)和乳腺良性病变组(80例),另选取80例健康体检者作为健康组。比较3组受试者CEA、CA125、CA153水平和阳性表达情况,以及不同病理特征乳腺癌患者CEA、CA125、CA153的阳性表达情况。以病理检查结果为金标准,比较CEA、CA125、CA153单独及联合检测对乳腺癌的诊断价值。结果乳腺癌组患者CEA、CA125、CA153水平和阳性表达率均高于乳腺良性病变组和健康组,差异均有统计学意义(P﹤0.05)。临床分期为Ⅲ~Ⅳ期、肿瘤大小≥5 cm、有淋巴结转移乳腺癌患者CEA、CA125、CA153的阳性表达率分别高于临床分期为Ⅰ~Ⅱ期、肿瘤大小﹤5 cm、无淋巴结转移的乳腺癌患者,差异均有统计学意义(P﹤0.05)。CEA、CA125、CA153联合检测诊断乳腺癌的准确度、灵敏度均高于各指标单独检测。结论CEA、CA125、CA153在乳腺癌患者中的表达水平和阳性表达率较高,与乳腺癌的发生及发展有关,三者联合检测对乳腺癌的诊断价值较高。 Objective To investigate the diagnostic value of single and combined detection of serum carcinoembryon-ic antigen(CEA),carbohydrate antigen(CA)125 and CA153 for breast cancer.Method A total of 172 breast disease pa-tients underwent breast surgery were selected and divided into breast cancer group(92 cases)and benign breast lesion group(80 cases)according to the postoperative pathological results.Another 80 healthy patients were selected as the healthy group.The levels and positive expression rates of CEA,CA125 and CA153 in three groups,and the positive ex-pression rates of CEA,CA125 and CA153 in breast cancer patients with different pathological characteristics were com-pared.Pathological examination results were used as the gold standard,the diagnostic value of CEA,CA125 and CA153 single and combined detection for breast cancer were compared.Result The levels and positive expression rates of CEA,CA125 and CA153 in breast cancer group were higher than those in benign breast lesion group and healthy group,and the differences were statistically significant(P<0.05).The positive expression rates of CEA,CA125 and CA153 in breast cancer patients with clinical stage III-IV,tumor size≥5 cm and lymph node metastasis were higher than those in breast cancer patients with clinical stage I-II,tumor size<5 cm and no lymph node metastasis,and the differences were statistically significant(P<0.05).The accuracy and sensitivity of CEA,CA125 and CA153 combined detection in the di-agnosis of breast cancer were higher than those of each index single detection.Conclusion The expression levels and positive expression rates of CEA,CA125 and CA153 in breast cancer patients are high,which are related to the occur-rence and development of breast cancer.The combined detection of CEA,CA125 and CA153 is of high diagnostic value for breast cancer.
作者 吴世园 罗蔚 姚俐霞 麻玲霞 WU Shiyuan;LUO Wei;YAO Lixia;MALingxia(Department of Laboratory,Huaihua City Maternal and Child Health Care Hospital,Huaihua 418000,Hu’nan,China;Department of Traditional Chinese Medicine,Huaihua City Maternal and Child Health Care Hospital,Huaihua 418000,Hu’nan,China)
出处 《癌症进展》 2024年第16期1802-1805,共4页 Oncology Progress
基金 湖南省中医药科研课题(D2024075)。
关键词 乳腺癌 癌胚抗原 糖类抗原125 糖类抗原153 诊断价值 breast cancer carcinoembryonic antigen carbohydrate antigen 125 carbohydrate antigen 153 diagnos-tic value
  • 相关文献

参考文献7

二级参考文献47

  • 1Cheung KL, Graves CR, RobertsonJF.Tumour marker measurements in the diagnosis and monitoring of breast cancerj]].Cancer Treat Rev ,2000,26(2) :91-102.
  • 2Jiang W, Freidlin B, Simon R.Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect[J]'J Nat! Cancer Inst,2007, 99( 13): 1036-1043.
  • 3Harris L, Fritsche H, Mennel R, et aI.American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cance[J J].J Clin Oncol, 2007,25(33): 5287-5312.
  • 4Molina R,AugeJM,Farms B,et aI.Prospective evaluation of car?cinoembryonic antigen (CEA )and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer[J].Clin Chern, 2010,56(7): 1148-1157.
  • 5Hayes OF, Zurawski VRJr,Kufe OW.Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancerj Lj.J Clin Oncol, 1986,4(10): 1542-1550.
  • 6Yerushalmi R, Tyldesley S, Kennecke H, et aI.Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correl?ation with outcomej Lj.Ann Oncol,2012,23(2):338-345.
  • 7Hashimoto K, Y onemori K, Katsumata N, et aI.Prediction of prog?ressive disease using tumor markers in metastatic breast cancer patients without target lesions in first-line chemotherapy[J].Ann Oncol,2010,21( 11) :2195-2200.
  • 8Jager W, Kissing A, Cilaci S, et aI. Is an increase in CA 125 in breast cancer patients an indicator of pleural metastases[J].B[J Cancer, 1994,70(3) :493-495.
  • 9Molina R, Barak V, van Dalen A, et aI.Tumor markers in breast cancer-European Group on Tumor Markers recommendations[J]. Tumour BioI, 2005 ,26(6): 281-293.
  • 10许隽颖,刘超英,李江,胡红,王润洁.肿瘤标志物CEA、CA15-3和CA125在乳腺癌化疗疗效评估中的价值[J].放射免疫学杂志,2009,22(2):160-162. 被引量:17

共引文献84

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部